中药降肝隆联合拉米夫定治疗活动性肝炎肝硬化的临床研究

Clinical Study on Treatment of Active Liver Cirrhosis with Jiangganlong and Lamivudine

目的:研究中药降肝隆联合拉米夫定治疗活动性肝炎肝硬化(ALC)的临床疗效。方法:随机选择ALC62例,用分层随机抽样法随机平均分为治疗组和对照组。治疗组采用中药降肝隆,每3天1剂,加拉米夫定0.1g/d;对照组采用退黄、保肝及对症治疗。疗程6～18个月。结果:治疗组血清HBV DNA阴转率90.32％(28/31),和对照组相比,差异有显著性意义(P<0.01);两组治疗后,血清总胆红素、丙氨酸转氨酶、球蛋白明显下降,白蛋白明显升高,两组相比,差异有显著性意义(P<0.01);B超示门静脉宽度变窄,两组相比,差异有显著性意义(P<0.05);临床存活率:治疗组为93.75％,对照组为74.19％,两组相比,差异有显著性意义(P<0.01)。结论:中药降肝隆联合拉米夫定治疗ALC,能抑制病毒复制,改善肝脏循环和肝功能,提高ALC的存活率。

Objective: To study the clinical treating affection of Jiangganlong and Iamivudine. on active liver cirrhosis. Methods: 62 cases of ALC, Were divided into treatment group and control group, randomly. Treatment group was treated with Jiangganlong a dose/3d and Lamivudine 0.1/d; Control group was treated with general treatment for 6 months Results: HBV DNA in the serum changed from positive to negative, the rate of treatment group was 93.32% (28/31), the control group 3.2% (1/31) (P<0.01). After treatment, the levels of total bilirubin (TBil)、ALT、 globulin (G) of treatment group were lower and allumin (A) was higher than control group (P<0.01). Wide of portal vein, checked with ultrasonic B showed that, the control group was wider than treatment group (P < 0.05). Existence rate, treatment group was 93.75 % , compared with control group 74.19% (P<0.01). Conclusion: The Effects of traditional herbs medicine with Lamivudine show that, HBV can be impressed, the liver microcirculation can be improved, and hepatic function can be improved, The existence rate of Patients with ALC in treatment group is higher than the control group.